Showing results (21-30 of 164) with videos related to
Sort By:
Pageof 17
Frontiers in Oncology|January 27, 2022
Targeting KRAS in Non-Small Cell Lung CancerElena Corral de la Fuente, Maria Eugenia Olmedo Garcia, Ana Gomez Rueda, et al.Actas Dermo-Sifiliograficas|June 27, 2006
[Gefitinib-induced perforating dermatosis]Montse Fernández-Guarino, Isabel Aldanondo, Carmen González-García, et al.Ecancermedicalscience|January 28, 2015
Metronomics for thymic carcinomaJacobo Muñoz Del Toro, Patricia Cortez Castedo, Alfonso Cortés Salgado, et al.Gynecologic Oncology|February 22, 2002
Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimenAntonio González-Martín, Carmen Crespo, José Luis García-López, et al.Case Reports in Oncological Medicine|July 26, 2021
Management of Intracranial Metastases in EGFR-Mutated NSCLC: A Review of Literature following an Unusual Case ReportVíctor Albarrán, Javier Pozas, Juan José Soto, et al.Lung Cancer (Amsterdam, Netherlands)|March 2, 2020
Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancerBenjamin Besse, Pilar Garrido, Alexis B Cortot, et al.Journal of Clinical Pharmacology|December 29, 2022
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid TumorsMichael J Hanley, Manolo D'Arcangelo, Enriqueta Felip, et al.Patient Preference and Adherence|May 14, 2016
Patient involvement in clinical research: why, when, and howJosé A Sacristán, Alfonso Aguarón, Cristina Avendaño-Solá, et al.Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|September 21, 2021
[Multidisciplinary consensus on optimizing the detection of NTRK gene alterations in tumours]Federico Rojo, Ramón Colomer, Fernando López-Ríos, et al.Clinical Lung Cancer|May 16, 2009
Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapyPilar Garrido, Rafael Rosell, Bartomeu Massutí, et al.Pageof 17